Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-r... Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -40 | 0.025 | 0.025 | 0.013 | 525096203 | 0.0155 | DE |
| 4 | -0.01 | -40 | 0.025 | 0.025 | 0.013 | 525096203 | 0.0155 | DE |
| 12 | -0.01 | -40 | 0.025 | 0.025 | 0.013 | 525096203 | 0.0155 | DE |
| 26 | -0.5875 | -97.510373444 | 0.6025 | 0.6025 | 0.013 | 262548102 | 0.0155 | DE |
| 52 | -0.5875 | -97.510373444 | 0.6025 | 0.6025 | 0.013 | 262548102 | 0.0155 | DE |
| 156 | -0.585 | -97.5 | 0.6 | 1.165 | 0.013 | 2773155 | 0.40343616 | DE |
| 260 | -1.47 | -98.9898989899 | 1.485 | 1.67 | 0.013 | 1532636 | 0.51354568 | DE |
lighter than AIR
3分前
gdl
4分前
Buckey
5分前
kegstackz
5分前
manibiotech
5分前
Sammy boy
6分前
jrlsss
6分前
biowin
7分前
Dennis14
7分前
hondaboost
7分前
againstallodds
7分前
Trum
8分前
ducci1
8分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。